Evidence map›Paper›PMID 33352765›Full record

ReviewBiology2020

Unravelling the Network of Nuclear Matrix Metalloproteinases for Targeted Drug Design.

Anastasia S Frolova, Anastasiia I Petushkova, Vladimir A Makarov, Surinder M Soond, Andrey A Zamyatnin

Open access · goldAbstract readReview
In one paragraph

Review in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Novel Roles of MT1-MMP and MMP-2: Beyond the Extracellular Milieu.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anastasia S FrolovaInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-6980-0028
Anastasiia I PetushkovaInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Vladimir A MakarovInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Surinder M SoondInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-7320-435X
Andrey A ZamyatninInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-3046-4565
Sechenov University · RU

Funding

Russian Science Foundation 16-15-10410
6 · The paper itself

Abstract

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are responsible for the degradation of a wide range of extracellular matrix proteins, which are involved in many cellular processes to ensure the normal development of tissues and organs. Overexpression of MMPs has been observed to facilitate cellular growth, migration, and metastasis of tumor cells during cancer progression. A growing number of these proteins are being found to exist in the nuclei of both healthy and tumor cells, thus highlighting their localization as having a genuine purpose in cellular homeostasis. The mechanism underlying nuclear transport and the effects of MMP nuclear translocation have not yet been fully elucidated. To date, nuclear MMPs appear to have a unique impact on cellular apoptosis and gene regulation, which can have effects on immune response and tumor progression, and thus present themselves as potential therapeutic targets in certain types of cancer or disease. Herein, we highlight and evaluate what progress has been made in this area of research, which clearly has some value as a specific and unique way of targeting the activity of nuclear matrix metalloproteinases within various cell types.

Indexed as

apoptosiscancerextracellular matriximmune responsematrix metalloproteinasenuclei

Identifiers

PMID33352765
PMCPMC7765953
OpenAlexW3115358426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.